Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Becaterin is a topical combination medication formulated with a corticosteroid, an aminoglycoside antibiotic, and an azole antifungal agent. It typically contains **betamethasone dipropionate**, **gentamicin sulfate**, and **clotrimazole**. This triple-action therapy is indicated for the treatment of inflammatory skin disorders (dermatoses) that are complicated by, or at risk of, secondary bacterial and fungal infections. Betamethasone provides potent anti-inflammatory, antipruritic, and vasoconstrictive effects by binding to glucocorticoid receptors. Gentamicin sulfate offers broad-spectrum antibacterial activity against susceptible Gram-positive and Gram-negative bacteria by inhibiting protein synthesis. Clotrimazole acts as a broad-spectrum antifungal by inhibiting the synthesis of ergosterol, a vital component of fungal cell membranes. The drug is commonly marketed in Latin American regions, such as Mexico, for conditions like infected eczema, tinea infections, and various forms of dermatitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Becaterin.